1442.5000 -10.20 (-0.70%)
NSE Dec 10, 2025 15:31 PM
Volume: 72,364
 

1442.50
-0.70%
ICICI Securities Limited
Tatva Chintan’s Q3FY23 revenue rose 15% YoY / 34% QoQ to Rs1.2bn as SDA revenue recovered to Rs0.6bn, up 6.4% YoY / 5.7x QoQ. However, non-SDA segments, which hitherto performed well, dipped QoQ. The disappointment come from an 800bps QoQ contraction in gross profit margin to 43.8% due to higher bromine and solvent prices, which have subsequently corrected.
Tatva Chintan Pharma Chem Ltd. is trading above its 200 day SMA of 1006.3
More from Tatva Chintan Pharma Chem Ltd.
Recommended